Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Paratek Pharmaceuticals stock | 6.21

Own Paratek Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Paratek Pharmaceuticals, Inc is a biotechnology business based in the US. Paratek Pharmaceuticals shares (PRTK) are listed on the NASDAQ and all prices are listed in US Dollars. Paratek Pharmaceuticals employs 101 staff and has a trailing 12-month revenue of around USD$39.9 million.

How to buy shares in Paratek Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Paratek Pharmaceuticals. Find the stock by name or ticker symbol: PRTK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Paratek Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$6.21, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Paratek Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Paratek Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Paratek Pharmaceuticals share price

Use our graph to track the performance of PRTK stocks over time.

Paratek Pharmaceuticals shares at a glance

Information last updated 2020-11-20.
Latest market close USD$6.21
52-week range USD$2.5 - USD$6.72
50-day moving average USD$5.375
200-day moving average USD$4.9523
Wall St. target price USD$17.4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.845

Buy Paratek Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Paratek Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Paratek Pharmaceuticals price performance over time

Historical closes compared with the close of $6.21 from 2020-11-16

1 week (2020-11-17) 0.49%
1 month (2020-10-23) 25.45%
3 months (2020-08-24) 32.41%
6 months (2020-05-23) N/A
1 year (2019-11-23) N/A
2 years (2018-11-23) -13.99%
3 years (2017-11-24) -69.63%
5 years (2015-11-24) -67.42%

Paratek Pharmaceuticals financials

Revenue TTM USD$39.9 million
Gross profit TTM USD$-26,494,000
Return on assets TTM -22.47%
Return on equity TTM 0%
Profit margin -248.05%
Book value $-0.421
Market capitalisation USD$276.6 million

TTM: trailing 12 months

Shorting Paratek Pharmaceuticals shares

There are currently 3.8 million Paratek Pharmaceuticals shares held short by investors – that's known as Paratek Pharmaceuticals's "short interest". This figure is 5.5% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting Paratek Pharmaceuticals shares can be evaluated.

Paratek Pharmaceuticals's "short interest ratio" (SIR)

Paratek Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Paratek Pharmaceuticals shares currently shorted divided by the average quantity of Paratek Pharmaceuticals shares traded daily (recently around 327606.25). Paratek Pharmaceuticals's SIR currently stands at 11.68. In other words for every 100,000 Paratek Pharmaceuticals shares traded daily on the market, roughly 11680 shares are currently held short.

However Paratek Pharmaceuticals's short interest can also be evaluated against the total number of Paratek Pharmaceuticals shares, or, against the total number of tradable Paratek Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Paratek Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Paratek Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.0878% of the tradable shares (for every 100,000 tradable Paratek Pharmaceuticals shares, roughly 88 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Paratek Pharmaceuticals.

Find out more about how you can short Paratek Pharmaceuticals stock.

Paratek Pharmaceuticals share dividends

We're not expecting Paratek Pharmaceuticals to pay a dividend over the next 12 months.

Have Paratek Pharmaceuticals's shares ever split?

Paratek Pharmaceuticals's shares were split on a 1:12 basis on 31 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Paratek Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Paratek Pharmaceuticals shares which in turn could have impacted Paratek Pharmaceuticals's share price.

Paratek Pharmaceuticals share price volatility

Over the last 12 months, Paratek Pharmaceuticals's shares have ranged in value from as little as $2.5 up to $6.72. A popular way to gauge a stock's volatility is its "beta".

PRTK.US volatility(beta: 1.49)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Paratek Pharmaceuticals's is 1.487. This would suggest that Paratek Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Paratek Pharmaceuticals overview

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site